阿尔索斯皮诺因A和B:CAT/GPX/TrxR的新型类调节剂,具有集成的ADMET和分子建模

相关实验视频

Updated: Jan 15, 2026

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

Syed Shams Ul Hassan¹, Wei Luo¹, Yan Ji¹

¹Shanghai Key Laboratory for Molecular Engineering of Chiral Drugs, Department of Pharmacy, Shanghai Jiao Tong University, Shanghai, 200240, PR China.

Chemico-biological interactions

|October 12, 2025

概括

来自 Alsophila spinulosa 的两种新型黄素,AlsoSpinones A和B,表现出强大的抗氧化活性. 它们有效地清除激素并调节关键的抗氧化酶,显示出药物设计的前景.

科学领域:

自然产品化学自然产品化学
药用化学医学化学
生物化学生物化学

背景情况:

寻找新型抗氧化剂对于对抗氧化应激至关重要.
是一种丰富的生物活性化合物的来源,具有潜在的治疗应用.
了解抗氧化剂作用机制是开发有效治疗方法的关键.

研究的目的:

为了分离和描述来自Alsophila spinulosa的新型黄化合物.
评估这些新型化合物的抗氧化潜力和作用机制.
为下一代抗氧化剂的开发提供结构导向的见解.

主要方法:

使用光谱技术分离和阐明黄的结构.
在体外抗氧化剂测定,包括DPPH基因清除和酶活性调制 (CAT,GSH,MDA).
分子对接和分子动力学模拟以调查酶-连接体相互作用.
用ADMET分析来评估类似药物的特性.

主要成果:

从Alsophila spinulosa中鉴定出了两个新的黄类化合物,也就是A和B类类化合物.
这两种化合物都显示出强大的DPPH激素清除活性和调节的抗氧化酶 (CAT,GPX,TrxR).
分子模拟显示了强烈的与抗氧化酶的结合亲和力,通过特定的相互作用稳定,以及有利的ADMET概况,特别是对于alsospinone B.

结论:

阿尔索斯宾A和B是有前途的抗氧化剂,具有有利的类似药物的特性.
该研究阐明了详细的作用机制,包括TrxR的全调节和结构-活性关系.
这些发现为设计新型抗氧化剂疗法提供了有价值的结构指导线索.

关键词:

接收人接收人也就是说,阿尔索菲拉 (Alsophila spinulosa) 是一个螺旋虫.具有抗氧化活性的抗氧化剂.黄类化合物黄类化合物机理机制机理机制分子对接是分子对接.

更多相关视频

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

Author Spotlight: Advancing Therapeutics to Treat Vibriosis in Humans and Aquatic Organisms

Author Spotlight: Advancing Therapeutics to Treat Vibriosis in Humans and Aquatic Organisms

Published on: May 31, 2024

相关概念视频

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...

GPCRs Regulate Adenylyl Cylase Activity

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...

Ligand Binding and Linkage

Ligand Binding and Linkage

Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...

Allosteric Proteins-ATCase

Allosteric Proteins-ATCase

Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...